Introduction {#S0005}
============

Coeliac disease (CD) is an auto-immune inflammatory reaction characterized by partial or total atrophy of the proximal small intestinal villi, occurring after ingestion of gluten in genetically predisposed patients \[[@CIT0001], [@CIT0002]\].

Inflammatory denudation of the villous surface gives rise to malabsorption of foodstuffs, folate, fat-soluble vitamins and iron. In children with severe mucosal damage, absorption of vitamins, zinc and protein is also affected \[[@CIT0003]\]. It is common in children and adolescents with a variety of disorders, including children with recurrent or persistent gastrointestinal symptoms, dermatitis herpetiformis, dental enamel defects, osteoporosis, short stature, delayed puberty, persistent iron deficiency anaemia, asymptomatic individuals with type 1 diabetes, Down syndrome, Turner syndrome, Williams syndrome, selective immunoglobulin (IgA) deficiency and first degree relatives of individuals with coeliac disease \[[@CIT0004], [@CIT0005]\].

Many children and adults with coeliac disease have non-classical forms of the illness. So-called silent coeliac disease refers to partial or complete villous atrophy in seropositive patients who have no gastrointestinal or extra-intestinal complications. Subclinical coeliac disease refers to villous atrophy in seropositive patients who have extra-intestinal complications but few or no gastrointestinal complaints \[[@CIT0006]\].

Troncone *et al*. \[[@CIT0007]\] reported a strong association between HLA class II genes (Dq molecule) and the pathogenesis of CD. Recent studies have shown that in the intestinal mucosa of coeliac patients, there are T-cells that recognize gliadin peptides when presented by the Dq heterodimer (A1\* 0501, B1\* 0201) \[[@CIT0008], [@CIT0009]\]. Children with autoimmune disorders such as type 1 diabetes, autoimmune thyroid disease and Sjogren\'s syndrome have a higher incidence of coeliac disease \[[@CIT0010]\].

The frequency of cases of CD with atypical manifestations, especially in older children and adults, the existence of latent forms of the disease, and the presence of groups of patients considered at high risk for developing CD, together with the need to monitor relapses and compliance to diet in diagnosed cases, have prompted the search for non-invasive serological screening methods \[[@CIT0011]\]. The use of serology resulted in an increased detection rate, although a true increase in incidence may have also occurred \[[@CIT0012]\].

Although intestinal biopsy is the gold standard for final diagnosis of CD and it is the only proof of a positive or negative response to a gluten-free diet \[[@CIT0013]\], three main categories of circulating antibodies have been identified with potential value in the diagnosis and screening of CD: anti-gliadin (AGA), anti-reticulin (ARA) and anti-endomysial antibodies (EMA). Anti-endomysial antibodies have largely replaced anti-reticulin antibodies because of their greater sensitivity \[[@CIT0014]\].

Tissue transglutaminase (tTG) has been identified as the main, if not sole, autoantigen recognized by endomysial antibodies in patients with CD. This enzyme, which is widely distributed in human organs, belongs to a family of calcium-dependent enzymes. IgA class tTG autoantibodies may be a useful tool in diagnosis and follow-up of CD \[[@CIT0007]\].

Scientific studies confirm that the average consumption of wheat of an Egyptian citizen is 150 kg per year. It is available mainly in bread, macaroni and other packed cake. There are difficulties in sticking to a gluten-free diet (GFD) in Egypt, it being less commercially available and more expensive \[[@CIT0015]\].

Our aim is to screen coeliac disease in Egyptian children with non-endocrinal short stature, refractory iron deficiency anaemia and type 1 diabetes; and also to evaluate the sensitivity and specificity of different serological tests for diagnosis of CD.

Material and methods {#S0006}
====================

It is a case control prospective study done after obtaining approval from the local institutional review board and human subjects protection. Written consent was obtained from patients and their parents.

This study included 292 patients, selected from the outpatient clinic of the National Research Centre and Cairo University Children\'s Hospital from 2004 to 2007. They represented the following groups (the number in each group related to the willingness of patients to enter the study and the prevalence of each disease).

Group I: patients with refractory iron deficiency anaemia (25 patients) {#S20007}
-----------------------------------------------------------------------

The study included 25 patients \< 18 years of age with refractory iron deficiency anaemia (not responding to iron therapy for 3 months in a dose of 6 mg elemental iron/kg/day).

The diagnosis of iron deficiency anaemia was based on the presence of haemoglobin concentration below the cut-off value of \< 11 g/dl for children 5 months to 5 years of age, reduced MCV \< 75 fl, increased RDW \> 14.5 and one or more of the following: serum ferritin \< 10 mg/dl (cut-off value of 12 mg/dl), serum iron \< 50 µg/dl and transferrin saturation% (serum iron/TIBC×100)\<15% \[[@CIT0016]\].

### Exclusion criteria

Prior erosive, ulcerative or malignant disease of the gastrointestinal tract.Previous gastrointestinal surgery.Overt gastrointestinal bleeding within the past 3 months.Inability to access the duodenum for biopsy.Patients with parasites causing chronic blood loss, i.e. *Ancylostoma* or bilharziasis.Presence of occult blood in stools.

Group II: patients with non-endocrinal short stature (67 patients) {#S20009}
------------------------------------------------------------------

### Inclusion criteria

Height greater than 2.5 SDS below the mean for age.Growth velocity less than expected for their age.Delayed bone age.

### Exclusion criteria

Familial short stature (according to mid-parental height).Constitutional delay of growth and puberty.Dysmorphic syndromes.Disproportional short stature (bone dysplasias and rickets).Chronic systemic diseases.Patients with endocrinal causes of short stature (primary hypothyroidism and growth hormone deficiency disorders in response to stimulation by ITT and clonidine tests).Turner syndrome diagnosed by karyotype.

Group III: patients with type I diabetes mellitus (200 patients) {#S20012}
----------------------------------------------------------------

They were selected among diabetics with variable duration of disease and variable glycosylated haemoglobin levels (controlled and uncontrolled).

All the above groups were subjected to full history taking (with special stress on the duration of disease and relation of symptoms to diet) and thorough clinical examination including anthropometric measurements (mainly weight and height, or length if needed). Height was determined with a Harpender stadiometer, weight was taken with standard underwear using a balance scale (Sica -- company).

Laboratory investigations {#S20013}
-------------------------

For antibody detection 5 ml of blood was obtained by venepuncture from each patient and sera were separated promptly, grossly haemolysed and lipaemic samples were excluded. The specimens were aliquoted and stored at −20°C until the time of analysis.

Laboratory investigations were done in the form of IgA anti-endomysium for patients with refractory iron deficiency anaemia and diabetes mellitus, IgA anti-gliadin for patients with short stature, and IgG antibodies to tissue transglutaminase for patients with refractory iron deficiency anaemia, while IgG anti-gliadin and IgA anti-reticulin was done for all patients included in the study.

Anti-gliadin antibody (AGA) detection was performed by a solid phase enzyme immunoassay (ELISA), using kits from Immco Diagnostics for IgG AGA (Immco -- USA/Canada). Anti-reticulin antibody (ARA) detection was performed by indirect immunofluorescence using a commercial kit from Immco Diagnostics (Immco -- USA/Canada). Anti-endomysial antibody (EMA) detection was performed by indirect immunofluorescence (using monkey oesophagus as a substrate) using a commercial kit from Immco Diagnostics (Immco -- USA/ Canada). Anti-tissue transglutaminase (TTG) IgG antibody detection was performed by an ELISA technique for the detection and semi-quantitation of anti-tissue transglutaminase IgG antibodies in human serum using a commercial kit from Immco Diagnostics (Immco -- USA/Canada).

In addition, upper gastrointestinal endoscopy with small intestinal biopsies was done for only 98 out of the 292 studied patients. These included all patients with refractory iron deficiency anaemia and short stature and only type 1 diabetics with positive coeliac antibodies that justified the invasive upper gastrointestinal tract (GIT) endoscopy (only 6 out of the 200 studied patients).

At least two biopsies from the jejunum were obtained using conventional endoscopic forceps (open cup 8 mm). Samples were carefully oriented on filter paper (Millipore) and fixed in 10% formalin. Biopsies were embedded in paraffin wax, cut in sections 5 µm thick, and stained with haematoxylin and eosin. Small bowel biopsies were evaluated by observers unaware of the clinical and endoscopic findings.

Coeliac disease was diagnosed with one or more positive serological tests and typical histological findings on jejunal biopsy: inflammatory enteropathy characterized by proliferation of intraepithelial lymphocytes, crypt hyperplasia and partial or complete atrophy of small intestinal villi \[[@CIT0017]\]. Jejunal biopsy is considered the gold standard for diagnosis of coeliac disease.

Follow-up biopsy 6--11 months after starting a gluten-free diet was performed in 9 patients only (3 patients presenting with short stature and the remaining 6 with insulin-dependent diabetes mellitus \[IDDM\]), while the remaining patients refused.

As jejunal biopsy is considered the gold standard and from the ethical point of view we could not perform biopsy in normal healthy children, patients with no villous atrophy were considered to be the control group.

Statistical analysis {#S20014}
--------------------

Data were summarized as percentages. Weight and height were transformed into SDS by the program Growth Vision version 2. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and diagnostic efficiency of all antibodies were calculated according to biopsy results \[[@CIT0012]\].

### Sensitivity

Sensitivity is defined analytically as the lowest amount of the analyte that can be detected. Epidemiologically, it is the measure of the ability to detect or identify CD.$$\text{Sensitivity} = \frac{\text{Number\ of\ true\ positives}}{\text{Number\ of\ true\ positives} + \text{number\ of\ false\ negatives}} \times 100.$$

### Specificity

Specificity means, analytically, the degree of interference in the assay by extraneous substances that may be present in the sample, and epidemiologically, it is the ability of the test to identify the population without CD. Specificity (negative in health) is calculated as follows:$$\text{Sensitivity} = \frac{\text{Number\ of\ true\ negatives}}{\text{Number\ of\ true\ negatives} + \text{number\ of\ false\ positives}} \times 100.$$

### The predictive values

The positive predictive value is the fraction of positive test results that are true positives. This is often rather low in CD markers, when the false positive rate of the test is high.$$\begin{matrix}
\text{Positive} \\
{\text{predictive} =} \\
\text{value} \\
\end{matrix}\frac{\text{True\ positives}}{\text{True\ positives} + \text{false\ positives}} \times 100.$$

It is the probability that a person with a positive result actually has the disease. Similarly, the negative predictive value is the probability that a person with a negative result does not have the disease.$$\begin{matrix}
\text{Negative} \\
{\text{predictive} =} \\
\text{value} \\
\end{matrix}\frac{\text{True\ negatives}}{\text{True\ negatives} + \text{false\ negatives}} \times 100.$$

Results {#S0018}
=======

This study included 292 patients with clinical risk of CD divided into 3 groups: group I: refractory iron deficiency anaemia (25 patients), group II: non-endocrinal short stature (67 patients) and group III: type 1 diabetes mellitus (200 patients).

Group I: the 25 patients with refractory iron deficiency anaemia included in the study (19 males and 6 females), with mean age 6.5±4.5 year (1.0--17.0 year), mean age at presentation of anaemia 1.6±0.9 year (1.0--4.0 year) and mean duration of anaemia 2.8±2.5 year (0.2--10.0 year). The mean height SDS was −1.8±2.2 (−5.1--2.8 SDS) and mean weight SDS was −2.0±1.3 (−3.9--1.4 SDS).

Eleven patients (44%) were diagnosed by jejunal biopsy as having coeliac disease. [Table I](#T0001){ref-type="table"} represents the symptoms and complications while [Table II](#T0002){ref-type="table"} represents the endoscopic and histopathological findings of the 11 coeliac disease patients presenting with refractory iron deficiency anaemia.

###### 

Symptoms and complications of coeliac disease in patients presenting with refractory iron deficiency anaemia

  Variables                                         Coeliac   
  ------------------------------------------------- --------- ------
  Anorexia                                          5         45.5
  Heartburn                                         3         27.3
  Dyspepsia                                         3         27.3
  Vomiting                                          2         18.2
  Abdominal distension                              2         18.2
  Abdominal pain                                    7         63.6
  Diarrhoea                                         5         45.5
  Underweight[\*](#TF0001){ref-type="table-fn"}     3         27.3
  Short Stature[\#](#TF0002){ref-type="table-fn"}   5         45.5
  Haematemesis                                      0         0

^\*^*Underweight = weight ≥ −2.5 (SDS) below the mean*

^\#^*Short stature = height ≥ −2.5 (SDS) below the mean*

###### 

Study of endoscopic and histopathological findings of coeliac and non-coeliac disease patients presenting with refractory iron deficiency anaemia

  Variables                                           Coeliac   Non-coeliac        
  --------------------------------------------------- --------- ------------- ---- ------
  Oesophagitis                                        3         27.3          8    57.1
  Gastritis                                           5         45.5          6    42.9
  Duodenitis                                          10        90.9          10   71.4
  Jejunitis                                           10        90.9          6    42.9
  J. Inflammation[\#](#TF0003){ref-type="table-fn"}   6         54.5          12   85.7

^\#^*Jejunal inflammation was detected by histopathological examination of jejunal biopsies*

Group II: the 67 short children included in this study (44 males and 23 females) had a male to female ratio of 1.9, and a mean age of 7.9 ±3.9 years (range 2--18 years), mean height of −3.5±0.7 SDS (range \[−2.5\]--\[−5.0\]), mean weight of −2.7±1 SDS and mean growth velocity 4.3±1.2 cm/year.

Twenty-three patients (34.3%) were diagnosed by jejunal biopsy as having coeliac disease. Fifteen patients out of the 23 (65.2%) had short stature as the only presentation. The rest had short stature in addition to other presentations ([Table III](#T0003){ref-type="table"}).Cases no. 1, 3, 8 and 13 (17.4%) had chronic diarrhoea with an age of onset less than 2 years.Case no. 3 had chronic diarrhoea and congenital myopathy.Case no. 9 had persistent hypocalcaemia and X-ray revealed osteoporosis.Case no. 5, 6 had anaemia and hepatomegaly and case no. 6 had atrial septal defect (ASD).Case no. 12 had failure to thrive.

###### 

Demographic data and serological tests of patients with positive biopsy for coeliac disease presenting with short stature

  No.   Age \[year\]   Sex   Presentation other than short stature                 AGA-IgG                                   AGA-IgA                                   ARA-IgA   Biopsy             Follow-up biopsy
  ----- -------------- ----- ----------------------------------------------------- ----------------------------------------- ----------------------------------------- --------- ------------------ -------------------------------------------------------------
  1     12             M     Ch. diarrhoea                                         4 ve                                      +ve                                       +ve       Grade III (V.A.)   --
  2     9              F                                                           113.1[\*](#TF0004){ref-type="table-fn"}   129.5[\*](#TF0004){ref-type="table-fn"}   +ve       Grade III (V.A.)   --
  3     7.5            F     Ch. diarrhoea+myopathy                                253[\*](#TF0004){ref-type="table-fn"}     268[\*](#TF0004){ref-type="table-fn"}     −ve       Grade III V.A.     Grade II V.A. myopathy improved
  4     10             M                                                           12.5                                      19.4                                      −ve       Grade I V.A.       --
  5     12             M     Anaemia, hepatomegaly                                 160.7[\*](#TF0004){ref-type="table-fn"}   20                                        −ve       Grade II V.A.      --
  6     6.7            M     Anaemia, hepatomegaly+A.S.D.                          96[\*](#TF0004){ref-type="table-fn"}      15.5                                      −ve       Grade II V.A.      --
  7     6.9            M                                                           4.5                                       18.5                                      −ve       Grade I V.A.       --
  8     5              M     Ch. diarrhoea                                         205.9[\*](#TF0004){ref-type="table-fn"}   11.6                                      −ve       Grade II V.A.      The condition improved after gluten-free diet before biopsy
  9     14             M     Pain in L.L. and persistent hypocalcaemia             +ve                                       −ve                                       +ve       Grade III V.A.     N. Intestine N. Ca level
  10    7              M                                                           +ve                                       −ve                                       −ve       Grade I V.A.       N. Intestine
  11    8              M                                                           151[\*](#TF0004){ref-type="table-fn"}     −ve                                       +ve       Grade III V.A.     
  12    11.8           F     Failure to thrive[\*](#TF0004){ref-type="table-fn"}   69[\*](#TF0004){ref-type="table-fn"}      +ve                                       +ve       Grade I V.A.       
  13    6              F     Vomiting diarrhoea                                    310[\*](#TF0004){ref-type="table-fn"}     −ve                                       +ve       Grade III V.A.     
  14    10.5           F                                                           116[\*](#TF0004){ref-type="table-fn"}     136[\*](#TF0004){ref-type="table-fn"}     +ve       Grade III V.A.     
  15    5              F                                                           75[\*](#TF0004){ref-type="table-fn"}      --                                        +ve       Grade III V.A.     
  16    10.4           M                                                           87.2[\*](#TF0004){ref-type="table-fn"}    68\*                                      +ve       Grade III V.A.     
  17    6.1            M                                                           78.4[\*](#TF0004){ref-type="table-fn"}    26.5                                      −ve       Grade II V.A.      
  18    4.3            F                                                           24.6                                      7                                         +ve       Grade I V.A.       
  19    3              M                                                           302[\*](#TF0004){ref-type="table-fn"}     17                                        +ve       Grade III V.A.     
  20    6              M                                                           321.4[\*](#TF0004){ref-type="table-fn"}   37.5                                      +ve       Grade III V.A.     
  21    5              F                                                           36                                        40                                        −ve       Grade I V.A.       
  22    4              M                                                           192[\*](#TF0004){ref-type="table-fn"}     47.5                                      −ve       Grade II V.A.      
  23    6              M                                                           128[\*](#TF0004){ref-type="table-fn"}     45                                        −ve       Grade II V.A.      

*^\*^Positive ASD: atrial septal defect, V.A. -- villous atrophy AGA: anti-gliadin antibody, S.S. -- short stature ARA: anti-reticulin antibody*

Group III: it included 200 patients with IDDM (116 females and 84 males) with mean chronological age of 11.4 year. Prevalence of CD among the 200 IDDM cases was 3% (6 cases), 5 female patients and 1 male patient with male/female ratio of 1/5. [Table IV](#T0004){ref-type="table"} shows the clinical data while [Table V](#T0005){ref-type="table"} shows the laboratory data of the 6 CD patients presenting with IDDM.

###### 

Clinical data of coeliac disease patients with insulin-dependant diabetes mellitus

  Case no.      Sex   CA (Y)   Age of onset IDDM (Y)   Duration of DM (Y)   GIT symptoms           Height SDS   Weight SDS
  ------------- ----- -------- ----------------------- -------------------- ---------------------- ------------ ------------
  I             F              10.0                    1.0                  Repeated vomiting                   
  •before GFD         11                                                                           +0.25        +0.5
  •after GFD          11.75                                                                        +0.25        +0.75
                                                                                                                
  II            F              12.0                    2.0                  Abdominal distension                
  •before GFD         14.0                                                                         −0.25        +0.75
  •after GFD          14.75                                                                        −0.25        +1.25
                                                                                                                
  III           F              1.0                     11.42                Recurrent diarrhoea                 
  •before GFD         12.42                                                                        −1.75        +0.5
  •after GFD          13.33                                                                        −2.0         +0.75
                                                                                                                
  IV            F              3.0                     6.0                  Recurrent diarrhoea                 
  •before GFD         9.0                                                   & distension           −2.75        −2.5
  •after GFD          9.92                                                                         −3.0         −2.0
                                                                                                                
  V             F              5.0                     8.5                  No GIT symptoms                     
  •before GFD         13.5                                                                         −2.25        −1.75
  •after GFD          14.42                                                                        −2.0         −0.5
                                                                                                                
  VI            M              4.0                     12.25                Persistent diarrhoea                
  •before GFD         16.25                                                                        −3.5         −3.5
  •after GFD          17.0                                                                         −3.25        −3.5

*\*CA -- chronological age, GIT -- gastrointestinal tract, F -- female, M -- male, GFD -- gluten-free diet*

###### 

Laboratory data of coeliac disease patients with insulin-dependant diabetes mellitus

  Case no.      Hb \[g%\]   HbA~1c~\[%\]   AGA \[Eu/ml\]   ARA   EMA   Biopsy
  ------------- ----------- -------------- --------------- ----- ----- ----------------
  I                                                                    Grade III
  •before GFD   12.0        10.5           6.0             +ve   +ve   V.A
  •after GFD    12.3        10.0           4.5             +ve   +ve   
                                                                       
  II                                                                   Grade II
  •before GFD   11.5        11.1           6.2             −ve   +ve   V.A
  •after GFD    11.8        11.7           5.8             −ve   +ve   
                                                                       
  III                                                                  Grade II
  •before GFD   11.6        12.0           11.6            +ve   −ve   V.A
  •after GFD    12.0        11.5           10.0            +ve   −ve   
                                                                       
  IV                                                                   Grade II & III
  •before GFD   11.5        10.5           30              +ve   +ve   V.A
  •after GFD    12.0        11.2           28              +ve   +ve   
                                                                       
  V                                                                    Grade II
  •before GFD   12.0        10.7           8.6             +ve   −ve   V.A
  •after GFD    11.5        8.9            6.0             +ve   −ve   
                                                                       
  VI                                                                   Grade II
  •before GFD   6.5         8.7            34              −ve   −ve   V.A
  •after GFD    10.0        6.9            38              −ve   −ve   

*V.A -- villous atrophy, GFD -- gluten-free diet, AGA -- anti-gliadin antibody, ARA -- anti-reticulin antibody, EMA -- endomysium antibody*

AGA (IgG) showed the highest sensitivity (80%) followed by TTG (72.7%). ARA (IgA) showed the highest specificity (95.6%) followed by EMA (94.7%) ([Table VI](#T0006){ref-type="table"}).

###### 

Sensitivity, specificity, PPV, NPV and accuracy of different antibodies of all studied patients. Total studied group (Total No.=292)

  Antibody    Sensitivity \[%\]   Specificity \[%\]   PPV \[%\]   NPV \[%\]   Accuracy \[%\]
  ----------- ------------------- ------------------- ----------- ----------- ----------------
  AGA (IgA)   17.0                93.2                57.1        68.3        67.2
  AGA (IgG)   80.0                92.9                64.0        96.7        91.1
  ARA (IgA)   57.5                95.6                67.6        93.4        90.4
  EMA (IgA)   70.6                94.7                52.2        97.5        92.9
  TTG (IgG)   72.7                85.7                80.0        80.0        80.0

*PPV -- positive predictive value, NPV -- negative predictive value, AGA -- anti-gliadin antibodies, ARA -- anti-reticulin antibodies, AEM -- anti-endomysium antibodies, TTG -- anti-tissue transglutaminase*

Discussion {#S0019}
==========

Coeliac disease or gluten sensitive enteropathy is a permanent intolerance of dietary gluten leading to mucosal damage in the proximal small bowel in genetically susceptible individuals, characterized by inflammation, crypt hyperplasia and villous atrophy which regress on withdrawal of gluten from the diet \[[@CIT0017]\].

Ravikumara *et al*. \[[@CIT0008]\] found the prevalence of CD in the Avon longitudinal study of parents and children to be at least 1%, and more than 90% of cases of CD in children pass undiagnosed.

In our study, CD was diagnosed in 11 (44.0%) out of the 25 refractory iron deficiency anaemia (IDA) studied patients.

The anaemia of CD can be microcytic or macrocytic, and both iron and folic acid deficiencies have been described. Iron deficiency is commonly seen in CD because of the frequent involvement of the proximal small intestine, where most iron absorption occurs \[[@CIT0019]\]. Because CD may result in intestinal malabsorption of iron, occult coeliac disease has been reported in 0 to 6% of adults presenting with iron deficiency anaemia (IDA) \[[@CIT0020]\]. On the other hand, the reported incidence of IDA in CD varies between 10 and 80%, depending on the diagnostic criteria used \[[@CIT0021]\]. Fisgin *et al*. \[[@CIT0022]\], Masjedizadeh *et al*. \[[@CIT0004]\], and Kalayci *et al*. \[[@CIT0023]\] reported an incidence of 54.5, 3.2 and 66.7% respectively of IDA in a group of children with CD, which is much higher than in the general population.

In the current study, the most common reported symptoms in patients with CD presenting with refractory IDA were: gastrointestinal symptoms in the form of abdominal pain (63.6%), diarrhoea and anorexia (45.5% each), dyspepsia and heartburn (27.3% each), vomiting and abdominal distension (18.2% each). Complications detected in those patients were short stature (45.5%), and underweight (27.3%). Mody *et al*. \[[@CIT0021]\] suggested that, although the association of IDA with CD is recognized, the setting is usually that of significant gastrointestinal symptoms and malabsorption and not a sole presenting sign.

Endoscopic and histopathological findings detected in patients with CD were duodenitis and jejunitis (90.9% each), gastritis (45.5%), oesophagitis (27.3%), hiatus hernia (18.2%) and jejunal inflammation detected by histopathological examination of jejunal biopsies (54.5%).

Bhadad *et al*. \[[@CIT0024]\] suggested that CD emerged as the single most common cause of short stature, followed by various endocrine disorders. Short stature by itself, even when GIT symptoms are totally absent, is an appropriate indication for jejunal biopsy.

Our study on group II patients (patients with non-endocrinal short stature) showed that 23 (34.3%) out of 67 biopsied cases revealed total or subtotal villous atrophy diagnostic of CD. Our results are in agreement with De Lecea *et al*. \[[@CIT0025]\], who reported an incidence of CD in short children ranging from 25 to 33.8%, while lower prevalence (12%) was reported by Czerwionka-Szaflarska *et al*. \[[@CIT0026]\]. This high prevalence of CD in our study may be related to the selection of a high risk group of short children after exclusion of endocrinal causes of short stature.

In the current study, follow-up intestinal biopsy was done for only 3 patients with non-endocrinal short stature who received a gluten-free diet (GFD) for 6 months following the first biopsy. Case no. 10, who presented with only short stature, showed normal intestinal biopsy findings. Case no. 9, who presented with pain in the lower limbs and limping in addition to short stature, persistent hypocalcaemia with increased levels of parathyroid hormone and alkaline phosphatase, and an X-ray revealing osteoporosis, improved following a gluten-free diet, the hypocalcaemia improved and jejunal biopsy revealed normal villi with no flattening. This is in agreement with Stazi *et al*. \[[@CIT0027]\], who reported that osteoporosis is an atypical presentation of CD. Case no. 3, who presented with chronic diarrhoea and congenital myopathy, showed slight improvement of jejunal biopsy, i.e. villous atrophy changed from grade III to grade II, AGA-IgG remained positive but both diarrhoea and myopathy were improved. This is probably related to poor compliance of the patient. Also, this is in agreement with Cakir *et al*. \[[@CIT0028]\], who reported that the rate of neurological problems is increased in children with CD. Neurological abnormalities should be carefully investigated early after the diagnosis of CD is made.

Coeliac disease is a life-long inflammatory autoimmune condition of the gastrointestinal tract affecting genetically susceptible individuals. The coexistence of CD and other autoimmune disorders, particularly IDDM, thyroid disease and dermatitis herpetiformis, has been reported by several authors \[[@CIT0017], [@CIT0029], [@CIT0030]\].

Screening of IDDM patients in our study for CD revealed that 6/200 (3%) (5 females and 1 male) had CD as confirmed by jejunal biopsy. The most frequently encountered clinical presentation of the CD cases in this study was GIT manifestations (5/6, 83.3%) in the form of repeated vomiting, abdominal distention and recurrent diarrhoea followed by anaemia with short stature (2/6, 33.3%) and repeated urinary tract infection (1/6, 16.6%). This agrees with Magazzu *et al*. \[[@CIT0031]\], who reported that among 250 IDDM studied patients, 8/250 (3.2%) have CD, 7/8 (87.5%) presented with GIT manifestations and 1/8 (12.5%) presented with short stature. In contrast, Kaspers *et al*. \[[@CIT0032]\] found that children with type 1 diabetes and CD were characterized by earlier onset of diabetes and decreased growth and weight gain.

The prevalence of CD in this study among 200 IDDM patients was nearly similar to that reported by Barera *et al*. \[[@CIT0033]\] (3.2%). However, it is lower than that reported by Salah *et al*. \[[@CIT0034]\] (4%), Goh and Banerjee \[[@CIT0035]\] (4.4%) and Novoa Medina *et al*. \[[@CIT0036]\] (8%). The prevalence of CD in our study among IDDM patients was based on the results of intestinal biopsy. But still this prevalence does not reflect the actual prevalence of CD because a biopsy specimen was not taken for all IDDM patients.

Follow-up serological screening after 9--11 months of a gluten-free diet (GFD) in CD patients (group III) revealed that all serological markers are still positive. Two explanations for this finding are possible: first, poor compliance of patients to GFD is a possibility, as there are difficulties in sticking to a GFD in Egypt, it being less commercially available and more expensive. Secondly, serological screening follow-up was performed after 9--11 months on a GFD, which may not be sufficient for serological markers to disappear from the serum. Mäki *et al*. \[[@CIT0037]\] reported that IgG AGA needs a long time, sometimes more than one year, to become negative. EMA was reported to persist for about 9 months, while ARA disappears in parallel with mucosal healing \[[@CIT0038]\].

The standard diagnostic criteria of CD included the presence of the characteristic anti-gliadin or anti-tissue transglutaminase antibodies in serum, flattened mucosa on intestinal biopsy, and improved symptoms on a gluten-free diet \[[@CIT0039]\].

In our study, serological screening tests for CD of all studied patients revealed that IgA EMA, IgG TTG, AGA (IgA), AGA (IgG) and ARA had sensitivity rates of 70.6, 72.7, 17.0, 80.0, 57.5%, respectively; the specificity rates were 94.7, 85.7, 93.2, 92.9 and 95.6%; positive predictive values were 52.2, 80.0, 57.1, 64.0 and 67.6%; and negative predictive values were 97.5, 80.0, 68.3, 96.7 and 93.4%, respectively.

Yachha *el al*. \[[@CIT0040]\] found that IgA EMA, IgA TTG, AGA (IgA) and AGA(IgG) had sensitivity rates of 83, 74, 61 and 74%, respectively; the specificity rates were 95, 100, 89 and 26%; positive predictive values were 95, 100, 88 and 55%; and negative predictive values were 82, 74, 65 and 45%, respectively. They concluded that IgA TTG is useful for the diagnosis of CD, with sensitivity and specificity rates comparable to those of EMA, and this test is well suited for use in tropical countries such as India.

The present findings of lower sensitivity of AGA (IgA), EMA and ARA may be attributed to poor immune response of patients or IgA deficiency, which was not tested for in the present study group, age dependency of both IgG AGA and EMA, different cut-off values of the serological antibodies as regards AGA, or variation in the interpretation of immunofluorescence used for both ARA and EMA.

Hill and Holmes \[[@CIT0041]\] reported that the diagnostic guidelines could be modified so that small bowel biopsy is no longer regarded as mandatory in patients with high tTG. This will avoid invasive procedures and may lead to more rapid diagnosis and earlier treatment for over half of new patients with CD. On the other hand, Rodrigues and Jenkins \[[@CIT0013]\] reported that the diagnosis of CD still requires upper gastrointestinal endoscopy and small bowel biopsy.

However, patients with other autoimmune diseases, such as autoimmune hepatitis and diabetes mellitus, can react positively with tTG by ELISA \[[@CIT0042]\]. In addition, CD can occur in patients with IgA deficiency with an incidence 10--15-fold higher than the general population. In patients with IgA deficiency with CD, IgA antibodies to gliadin, endomysium, reticulin and tTG are usually negative. Such patients with IgA deficient CD are positive for IgG AGA. However, not all IgA deficient patients with CD are positive for IgG AGA. Thus, IgG EMA and IgG tTG are useful screening tests especially in patients with IgA deficiency \[[@CIT0043]\].

A limitation of our study was the number of patients and written consent from parents of children for doing jejunal biopsy and cost of kits.

In conclusion, coeliac disease is more common in Egyptian children with refractory iron deficiency anaemia, non-endocrinal short stature and type 1 diabetes than was previously thought. Screening of high-risk groups, and of patients with such common symptoms, is becoming an accepted standard in practice.

Coeliac disease is frequently under-diagnosed because of its protean presentations. Serological tests showed fairly good sensitivity and specificity in our study. The advent of serological markers with high sensitivity and specificity is changing our understanding of the disease and its prevalence. However, intestinal biopsy remains the cornerstone for definitive diagnosis of CD in patients with immunological reaction to gluten.

From this study, we suggest that the basis for diagnosis of CD in children should be through early case-finding by a) knowledge about different presentations of the disease and factors affecting them, b) generous serological testing in patients with vague symptoms, and c) screening of risk groups.

Encouragement of diagnosed children and adolescents with CD to receive a gluten-free diet to prevent the occurrence of serious complications attributed to this disease is highly recommended.
